In the third quarter, we also reported our first full quarter of cost of goods for product sales, with a gross profit margin of 92%, which is similar to a branded pharmaceutical product along with a clear value proposition for hospital systems to save money using Quellimmune. We believe this affords us an opportunity to generate future cash, reducing the amount of cash we need to raise to fund operations. Now turning our efforts on the neutralized AKI trial, we completed the interim analysis enabling us to ...